Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst(Yale Cancer Center), Paul Baas(Amsterdam UMC Location University of Amsterdam), Dong‐Wan Kim(Seoul National University Hospital), Enriqueta Felip(Vall d'Hebron Hospital Universitari), José Luis Perez‐Gracia(Clinica Universidad de Navarra), Ji‐Youn Han(National Cancer Center), Julian R. Molina(Mayo Clinic in Arizona), Joo-Hang Kim(CHA University Bundang Medical Center), Catherine Dubos Arvis(Centre François Baclesse), Myung‐Ju Ahn(Samsung Medical Center), Margarita Majem(Hospital de Sant Pau), Mary J. Fidler(Rush University Medical Center), Gilberto de Castro(Instituto do Câncer do Estado de São Paulo), Marcelo Garrido(Pontificia Universidad Católica de Chile), Gregory M. Lubiniecki(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yue Shentu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ellie Im(Merck & Co., Inc., Rahway, NJ, USA (United States)), Marisa Dolled‐Filhart(Merck & Co., Inc., Rahway, NJ, USA (United States)), Edward B. Garon(University of California, Los Angeles)
Cited by 6,512
Abstract
Related Papers
No related papers found
Powered by citation graph analysis